一项前瞻性、单中心、随机、双盲对照研究方案:长期口服甲硝唑能否有效降低结直肠癌患者术后肝转移发生率
约15%至25%的结直肠癌患者确诊时即合并肝转移,另有15%至25%的患者在原发性结直肠癌根治性切除后发生肝转移,其中绝大多数(80%至90%)肝转移初诊时无法根治性切除。结直肠癌肝转移也是结直肠癌患者的主要死因。近年来多项研究表明肠道菌群尤其是具核梭杆菌在结直肠癌肝转移发生中起关键作用,因此研究者假设长期使用甲硝唑可有效降低结直肠癌患者术后肝转移发生率。本研究为前瞻性、单中心、随机、双盲对照研究,拟将300例患者按1:1随机分配至试验组或对照组,旨在证明长期口服抗生素可有效降低结直肠癌患者术后肝转移发生率。
要点
- 结直肠癌确诊时15%至25%合并肝转移,根治术后另有15%至25%发生肝转移,其中80%至90%初诊无法根治性切除。
- 肠道菌群尤其是具核梭杆菌被认为在结直肠癌肝转移中起关键作用,据此假设长期口服甲硝唑可降低术后肝转移发生率。
- 本研究为前瞻性、单中心、随机、双盲对照研究,拟纳入300例患者按1:1随机分组。
核心结论
- 研究假设长期口服甲硝唑可有效降低结直肠癌患者术后肝转移发生率,本方案旨在验证长期口服抗生素能否有效降低该发生率。
研究设计与样本
- 本研究为前瞻性、单中心、随机、双盲对照研究,拟纳入300例患者,按1:1分配比例随机分配至试验组或对照组。
- 研究方案已获中国临床试验注册伦理委员会批准(ChiECRCT20210229),并于2021年7月5日在中国临床试验注册中心注册(ChiCTR2100046201)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Fifteen to 25% of patients with colorectal cancer have combined liver metastases at the time of diagnosis, whereas an additional 15 to 25% will develop liver metastases after curative resection of primary colorectal cancer, with the vast majority (80-90%) of liver metastases unresponsive to curative resection at first. Colorectal cancer liver metastasis is also the leading cause of death in patients with colorectal cancer. In recent years, several studies have demonstrated that intestinal flora, especially Fusobacterium nucleatum, plays a crucial role in the development of colorectal cancer liver metastasis, so we hypothesized that long-term metronidazole use could effectively reduce the incidence of postoperative liver metastasis in colorectal cancer patients. METHODS/DESIGN: This study is a prospective, single-centre, randomized, double-blind controlled study in which 300 patients will be randomly assigned to the test group or the control group in a 1:1 allocation ratio. The aim of this trial is to demonstrate that long-term oral antibiotics can effectively reduce the incidence of postoperative liver metastasis in patients with colorectal cancer. ETHICS AND DISSEMINATION: Ethics approval was obtained from the Ethics Committee at the Chinese Ethics Committee of Registering Clinical Trials (ChiECRCT20210229). The results of this study will be disseminated at several research conferences and as published articles in peer-reviewed journals. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2100046201. Registered on July 05, 2021.
引用
- Gao RQ, Mo ZC, Zhou HK, et al. A prospective, single-centre, randomized, double-blind controlled study protocol to study whether long-term oral metronidazole can effectively reduce the incidence of postoperative liver metastasis in patients with colorectal cancer. Trials. 2023. PMID: 38049888. doi:10.1186/s13063-023-07628-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。